Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Price Down 4.8%

Adaptimmune Therapeutics plc (NASDAQ:ADAP)’s share price traded down 4.8% during trading on Tuesday . The company traded as low as $1.00 and last traded at $1.00. 507,917 shares changed hands during trading, a decline of 72% from the average session volume of 1,785,425 shares. The stock had previously closed at $1.05.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on Adaptimmune Therapeutics in a research report on Friday, December 29th. They set a “hold” rating for the company.

Adaptimmune Therapeutics Price Performance

The company has a market cap of $981.29 million, a PE ratio of -1.79 and a beta of 2.39. The business has a 50-day moving average of $1.41 and a 200 day moving average of $0.92.

Adaptimmune Therapeutics (NASDAQ:ADAP) last issued its quarterly earnings results on Wednesday, March 6th. The biotechnology company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.12). The company had revenue of $0.23 million during the quarter, compared to analysts’ expectations of $4.80 million. Adaptimmune Therapeutics had a negative return on equity of 155.39% and a negative net margin of 188.90%. On average, equities analysts predict that Adaptimmune Therapeutics plc will post -0.44 EPS for the current fiscal year.

Institutional Trading of Adaptimmune Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Harbor Capital Advisors Inc. increased its position in Adaptimmune Therapeutics by 9.9% in the fourth quarter. Harbor Capital Advisors Inc. now owns 147,732 shares of the biotechnology company’s stock worth $117,000 after buying an additional 13,317 shares in the last quarter. Columbia Advisory Partners LLC purchased a new stake in Adaptimmune Therapeutics in the first quarter worth about $25,000. State Street Corp increased its position in Adaptimmune Therapeutics by 5.9% in the first quarter. State Street Corp now owns 284,741 shares of the biotechnology company’s stock worth $310,000 after buying an additional 15,943 shares in the last quarter. Goldman Sachs Group Inc. grew its position in shares of Adaptimmune Therapeutics by 56.4% during the second quarter. Goldman Sachs Group Inc. now owns 48,077 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 17,332 shares in the last quarter. Finally, Key Client Fiduciary Advisors LLC grew its position in shares of Adaptimmune Therapeutics by 6.4% during the fourth quarter. Key Client Fiduciary Advisors LLC now owns 336,620 shares of the biotechnology company’s stock worth $267,000 after purchasing an additional 20,295 shares in the last quarter. Hedge funds and other institutional investors own 31.37% of the company’s stock.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.